MedTrace Logo

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administration of AJH-2947 in Healthy Korean and/or Caucasian Adult Male Subjects

NCT06155487 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2026-08-13

No results posted yet for this study

Summary

The purpose of this randomized, double-blind, placebo-controlled Phase 1 study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of AJH-2947 in healthy Korean or Caucasian adult male participants.

Conditions

  • Healthy Volunteers
  • Chronic Pain Syndrome

Interventions

DRUG

AJH-2947 tablets or placebo

Administration: Oral

Sponsors & Collaborators

  • Seoul National University Hospital

    collaborator OTHER

  • JMackem Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Seung-Hwan Lee, MD. Ph.D · Seoul National University Clinical Trials Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-05
Primary Completion
2026-04-28
Completion
2026-04-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06155487 on ClinicalTrials.gov